Clinical Trial Update: PI3Kβ Selective Inhibitor With Paclitaxel, Advanced Gastric Adenocarcinoma [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial sponsored by Yonsei University evaluated a PI3Kβ-selective inhibitor in combination with paclitaxel for advanced gastric adenocarcino…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Adenocarcinoma

Drugs mentioned

• PACLITAXEL (PACLITAXEL)
• PI3Kβ selective inhibitor (PI3Kβ inhibitor)

Snippet

Sponsor: Yonsei University | Conditions: Advanced Gastric Adenocarcinoma | Phase 1, Phase 2 | Status: COMPLETED